Innovating Clinical Trials - A special 4-part podcast series

Welcome to Innovating Clinical Trials, a special edition podcast series produced by The Scientist’s Creative Services Team.

This series is brought to you by Amgen, a pioneer in the science of using living cells to make biologic medicines. They helped invent the processes and tools that built the global biotech industry, and have since reached millions of patients suffering from serious illnesses around the world with their medicines.

Clinical trials are desperate for innovation. Speed and efficiency need to improve as many patients cannot wait over a decade for new, potentially lifesaving medicines, and trial participants often do not reflect the patient population. Because clinical trials are complex and multidisciplinary, there is not a single, simple solution for accelerating progress. In this series, Rob Lenz, senior vice president of Global Development at Amgen, explores the latest approaches in clinical trial design and execution and highlights real-world examples of how scientists can run trials better and faster to develop optimal medicines that benefit patients.

Sign up now to receive an email when each podcast episode airs.
  • Episode 1 - Operational Innovation
    September 1, 2022
  • Episode 2 - Real World Data in Drug Development
    September 8, 2022
  • Episode 3 - The Right Patients
    September 15, 2022
  • Episode 4 - Real-World Clinical Trial Design and Execution in Oncology
    September 22, 2022
Visit this page to sign up for the Innovating Clinical Trials Q&A event, airing soon!
  • Webinar - Innovating Clinical Trials
    September 28, 2022 @ 2:30 PM ET




Rob Lenz, MD, PhD
Senior Vice President
Global Development



Sign up and listen now

Information you provide will be held in confidence and will be shared with the sponsoring vendor(s) of these podcasts. We may use the information to contact you about your account and to let you know about related programs and products; you may opt-out at any time. This allows The Scientist to keep these podcasts free of charge for our readers.